Compass Pathways reported new 26-week Phase 3 COMP006 data supporting the durability and safety profile of COMP360 for treatment-resistant depression. The company said results further underpin its path toward a potential U.S. launch in the first half of 2027. Overall, the update is constructive for the clinical confidence around COMP360 ahead of the planned regulatory timeline.
Compass Pathways reported new 26-week Phase 3 COMP006 data supporting the durability and safety profile of COMP360 for treatment-resistant depression. The company said results further underpin its path toward a potential U.S. launch in the first half of 2027. Overall, the update is constructive for the clinical confidence around COMP360 ahead of the planned regulatory timeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
